CTS
Ceretas Ltd
$0.9450
▲ +0.53%
Market cap
$46M
Turnover
$24,284
Last price
$0.9450
Day change
+0.53%
Announcements
5
Range, past year
Open 0.510 · Low 0.460 · Now 0.945 · High 1.110
Open CTS in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CTS momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
25/100
Wyckoff phase
Accumulation33d
Trend stage
Emerging
1 Day
+0.0%
1 Week
+3.8%
1 Month
-2.6%
RSI
57
Avg daily range
3.5%
Ceretas Ltd scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.
On the Wyckoff cycle it sits in Accumulation, where it has been for 33 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
What stands out
- RSI in healthy zone (57)
Points to watch
- 60d drawdown -21.3%
- Thin liquidity
CTS announcements
Recent price-sensitive releases.
- 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-29 First Patient Enrolled in Phase 2 CERE-CALM Clinical Trial Progress Report
- 2026-09-16 Milestone 3 Completed for CUREator Program Progress Report
- 2026-08-31 Ethics Committee Approval Secured for Additional Trial Sites Progress Report
- 2026-08-31 Appendix 4E & Annual Report 30 June 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
More Health Care stocks
Most traded in the same sector.